Sugammadex on Laparoscopic Bariatric Surgery

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Laparoscopic Bariatric SurgerySugammadex
Interventions
DRUG

Sugammadex

When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).

DRUG

Neostigmine

When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).

All Listed Sponsors
lead

Shanxi Bethune Hospital

OTHER

NCT06678451 - Sugammadex on Laparoscopic Bariatric Surgery | Biotech Hunter | Biotech Hunter